The company has substantially advanced the course of an novel therapy for ATTR-CM, leveraging the compound. Early patient data indicates potential improvements for those suffering by this debilitating disease. The focus https://biotech914179.timeblog.net/78037193/company-progresses-amyloidosis-management-using-the-therapy